| Autor: |
Tamara W van Hal, Juul MPA Van den Reek, Hans MM Groenewoud, Marcel C Pasch, Frank HJ Van den Hoogen, Mark H Wenink, Elke MGJ De Jong |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
JMIR Research Protocols, Vol 10, Iss 11, p e31647 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1929-0748 |
| DOI: |
10.2196/31647 |
| Popis: |
BackgroundOne in three patients with psoriasis will develop psoriatic arthritis (PsA). If left untreated, this can lead to pain, impaired function, and irreversible joint damage. Timely recognition and referral to a rheumatologist are therefore key. However, current methods used to screen patients with psoriasis for those who might benefit from referral to a rheumatologist are not performing well enough. ObjectiveThe Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) study is designed to determine the prevalence of PsA in a psoriasis population and to find parameters that can be used to develop a new or enhance an existing instrument for a rheumatological referral. MethodsDAPPER is a longitudinal observational study with a 1-year follow-up. Patients with psoriasis (N=300) who are treated at an outpatient dermatological clinic will be screened extensively for signs and symptoms of PsA by a trained rheumatologist. If there is clinical suspicion of PsA and the patient is not yet treated by a rheumatologist, referral to the Department of Rheumatology will follow for confirmation of the diagnosis and further care. After 1 year, data on changes in quality of life and PsA and psoriasis disease activity will be collected from the referred patients. The screening visit will be used to gather demographical and medical data, which can later be used to develop the aforementioned screening instrument. ResultsInclusion started in June 2019 and finished in June 2021. Follow-up with newly discovered patients with PsA is ongoing. ConclusionsThe DAPPER study is specifically designed to improve the detection of existing PsA in a dermatologic outpatient setting. Although internal validity will be tested, external validity will have to be checked using a second validation cohort. To predict the development of PsA in the future, longitudinal/prospective data collection is required and will be performed in a follow-up study (DAPPER-i). Trial RegistrationDutch Trial Register NTR7604; https://www.trialregister.nl/trial/7397 International Registered Report Identifier (IRRID)DERR1-10.2196/31647 |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
